Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is a purchase of 238 ordinary shares by Mr. SM Bicknell. The transaction occurred on November 11, 2009, within an Individual Savings Account (ISA) at a price of £12.48 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the share purchase.
Investor Verification Points
- Verify the identity of Mr. SM Bicknell and his role within the company to assess the significance of the insider purchase.
- Confirm the share price of £12.48 against the market price on November 11, 2009.
- Note that this filing does not reflect the company's broader financial health or operational results for the period.